TICKERNERD
Menu
PGNYPGNYHealthcare · Healthcare Plans

PGNY Stock Forecast: Progyny, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$26
+1.51% on the day

The 11 Wall Street analysts covering Progyny, Inc. hold a median 12-month price target of $34 — +29.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
97 / 100
Median analyst target
$34
Analysts covering
11
Total return, dividends reinvested
1W
−6.5%
1M
−18.8%
YTD
+2.3%
1Y
+16.5%
From 52W high
−18.8%
From 52W low
+61.2%
$16
$32
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PGNY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Progyny, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
94
Issuance
93
Accruals
87
Value
86
Growth
78
Volatility
77
Momentum
66
Revisions
51
Size
36

Quality (94): The business earns solid, repeatable profits on what it owns.

Revisions (51): Analysts have, on balance, been cutting their forecasts.

Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PGNY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PGNY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26PGNYHigh $40Median $34Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $27Median $34High $40

The green dot is the last close — the median target sits +29.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
13 Aug 2026Truist SecuritiesMaintainsBuy$33 → $36
12 Aug 2026BarclaysMaintainsEqual-Weight$34 → $30
28 July 2026BarclaysDowngradeEqual-Weight$27 → $34
28 July 2026BarclaysDowngradeEqual-Weight—
24 July 2026BTIGMaintainsBuy$30 → $40
24 July 2026BTIGMaintainsBuy—
21 July 2026Canaccord GenuityMaintainsBuy—
21 July 2026Canaccord GenuityMaintainsBuy$30 → $36
13 July 2026KeybancMaintainsOverweight—
13 July 2026KeybancMaintainsOverweight$30 → $35
22 June 2026Truist SecuritiesMaintainsBuy—
2 June 2026B of A SecuritiesMaintainsBuy—
19 May 2026Canaccord GenuityUpgradeBuy—
18 May 2026BarclaysMaintainsOverweight—
11 May 2026CitizensMaintainsMarket Outperform—
11 May 2026Truist SecuritiesMaintainsBuy—
20 Mar 2026BarclaysMaintainsOverweight—
11 Mar 2026Canaccord GenuityMaintainsHold—
5 Mar 2026BTIGMaintainsBuy—
2 Mar 2026KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PGNY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PGNY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+6.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Progyny, Inc. (PGNY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.6×

Cheaper than 29% of US stocks

Price / sales
1.5×

Cheaper than 61% of US stocks

Price / book
4.5×

Cheaper than 25% of US stocks

EV / EBITDA
14.5×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
5.3%

Higher than 40% of US stocks

Earnings growth (YoY)
63.9%

Higher than 79% of US stocks

Gross margin
25.5%

Higher than 29% of US stocks

Operating margin
11.4%

Higher than 66% of US stocks

Net margin
6.0%

Higher than 62% of US stocks

Returns & dividend
Return on equity
16.2%

Higher than 76% of US stocks

Return on assets
10.1%

Higher than 92% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PGNY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
PGNYProgyny, Inc.$2.0B
97
CLOVClover Health Investments Corp.$2.3B
67
ALHCAlignment Healthcare, Inc.$2.7B
69
OSCROscar Health, Inc.$9.2B
83
MOHMolina Healthcare, Inc.$10.6B
31
CNCCentene Corp.$32.5B
91
KARDKardigan, Inc.*$2.0B
0

* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Progyny, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PGNY news & analysis

Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks

Zacks Investment Research · 10 Aug 2026positive

Zacks Investment Research named Progyny, Inc. (PGNY) among four top-ranked liquid stocks, alongside IVZ, HUBS and HNGE, citing strong liquidity, growth attributes and operational efficiency for each.

Why it matters — A PGNY watcher would care because the company was singled out by Zacks as one of the top liquid stocks with strong growth and operational efficiency, which could raise its visibility among investors.

Why Progyny Stock Plunged, Then Gradually Recovered Today

The Motley Fool · 7 Aug 2026negative

Progyny's second-quarter sales and adjusted earnings per share grew by 5% and 15%, respectively, but the stock fell after management issued conservative guidance for 7%–11% revenue growth in the third quarter. The stock later recovered some of its losses over the course of the trading day.

Why it matters — The market's reaction to management's cautious Q3 revenue forecast, despite solid quarterly results, highlights how sensitive Progyny's valuation is to forward-looking guidance.

Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference

GlobeNewsWire · 7 Aug 2026neutral

Progyny, Inc. announced that its CEO, Pete Anevski, will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET.

Why it matters — A PGNY watcher would care because the presentation offers an opportunity to hear directly from the company's leadership at a notable industry conference.

Progyny Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

Progyny reported record quarterly revenue, gross profit, and adjusted EBITDA for Q2 2026. Management noted that early sales commitments and client-retention activity have positioned the company favorably for the 2027 selling season.

Why it matters — A PGNY watcher would care because record financial results and strong early positioning for the 2027 selling season signal robust business momentum and client confidence.

Progyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Progyny, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha.

Why it matters — The earnings call transcript gives PGNY watchers a record of what management said on the company's quarterly results.

FAQ

Frequently asked questions about PGNY stock

What is the PGNY stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Progyny, Inc. have a median 12-month price target of $34, with estimates ranging from $27 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PGNY stock a buy right now?

Of the 11 analysts covering Progyny, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Progyny, Inc. 97 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PGNY?

As at 13 Aug 2026, Progyny, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).

Will PGNY stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +29.4% from the last close, and Ticker Nerd's factor model ranks Progyny, Inc. 97 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PGNY stock forecast for 2030?

No analyst covering Progyny, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PGNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $40 over the next 12 months.

How has PGNY stock performed over the past year?

Progyny, Inc. returned +16.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Progyny, Inc. do?

Progyny Inc. is a leading provider of comprehensive fertility, family building, and women's health benefits solutions designed for employers, health plans, and benefit purchasers.

What is the latest news on PGNY?

The most recent item we track (Zacks Investment Research, 10 Aug 2026): "Boost Your Portfolio Returns With These 4 Top-Ranked Liquid Stocks". Zacks Investment Research named Progyny, Inc. (PGNY) among four top-ranked liquid stocks, alongside IVZ, HUBS and HNGE, citing strong liquidity, growth attributes and operational efficiency for each.

Company

About Progyny, Inc.

Progyny Inc. is a leading provider of comprehensive fertility, family building, and women's health benefits solutions designed for employers, health plans, and benefit purchasers. Its data-driven model delivers cohesive care from preconception through fertility, pregnancy, postpartum, return-to-work support, menopause, and midlife, empowering members with personalized clinical coaching, high-touch concierge services, and seamless access to in-person and virtual care. Progyny manages an actively managed network of top-tier women's health providers, including fertility specialists, reproductive endocrinologists, doulas, lactation consultants, and menopause experts, all NCQA-accredited in credentialing. The platform supports diverse paths to parenthood, such as adoption, surrogacy, and assisted reproductive technologies, alongside integrated prescription management and digital tools for global workforces. By focusing on superior clinical outcomes, member experiences, and cost efficiencies, Progyny integrates flexibly into existing benefit ecosystems across numerous industries, fostering healthier journeys at life's key milestones.

CEO Mr. Peter Anevski CPA · 835 employees · United States · https://www.progyny.com